[Skip to Navigation]
Article
June 1967

Chronic Myelogenous Leukemia: Possible Association With Reticulum Cell Sarcoma

Author Affiliations

Washington, DC

From the Hematology Research Section, Veterans Administration Hospital, Washington, DC. Dr. Libre was formerly a Postdoctoral Fellow in Hematology, Veterans Administration Hospital, Washington, DC; he is presently with the Clinical Hematology Branch, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Md.

Arch Intern Med. 1967;119(6):626-630. doi:10.1001/archinte.1967.00290240148015
Abstract

THE CONCEPTS of myeloproliferative and lymphoproliferative diseases provide a fluid nosology which interrelates hematologic malignancies on the basis of a common organ system or cell line of origin.1 Thus associated processes are recognized, and within the two broad categories, mergers and transformations from one clinical syndrome to another are relatively common. For example, the patient with chronic myelogenous leukemia (CML) may develop acute leukemia terminally. Giant follicular lymphoma can progress to lymphosarcoma, and lymphosarcoma frequently develops a leukemic phase. Changes that do occur tend to remain within the confines of either one or the other broad category, and transformation from a disease in the myeloproliferative group to one in the lymphoproliferative category would be unusual. Accordingly the coexistence in a patient of CML and reticulum cell sarcoma (RCS) appears, superficially, to be contrary to the usual concepts. The present report concerns a patient with blood and bone marrow findings

×